Literature DB >> 15191791

Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development.

Soumyajit Majumdar1, Sridhar Duvvuri, Ashim K Mitra.   

Abstract

The bioavailability of drugs is often severely limited due to the presence of biological barriers in the form of epithelial tight junctions, efflux proteins and enzymatic degradation. Physicochemical properties, such as lipophilicity, molecular weight, charge, etc., also play key roles in determining the permeation properties of drug candidates. As a result, many potential drug candidates may be dropped from the initial screening portfolio. Prodrug derivatization targeting transporters and receptors expressed on mammalian cells holds tremendous potential. Enhanced cellular delivery can significantly improve drug absorption. Such approaches of drug targeting and delivery have been the subject of intense research. Various prodrugs have been designed that demonstrate enhanced bioavailability and tissue specificity. This approach is equally applicable to human and veterinary pharmaceuticals since most of the transporters and receptors expressed by human tissues are also expressed in animals. This review highlights studies conducted on the use of transporters and receptors in an effort to improve drug bioavailability and to develop targeted drug delivery systems.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191791     DOI: 10.1016/j.addr.2004.02.006

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  24 in total

Review 1.  Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2012-04

Review 2.  Prodrug approaches for CNS delivery.

Authors:  Jarkko Rautio; Krista Laine; Mikko Gynther; Jouko Savolainen
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

Review 3.  Getting across the cell membrane: an overview for small molecules, peptides, and proteins.

Authors:  Nicole J Yang; Marlon J Hinner
Journal:  Methods Mol Biol       Date:  2015

Review 4.  Novel strategies for anterior segment ocular drug delivery.

Authors:  Kishore Cholkar; Sulabh P Patel; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-05       Impact factor: 2.671

5.  Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.

Authors:  Mitesh Patel; Ye Sheng; Nanda K Mandava; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2014-09-26       Impact factor: 5.875

6.  Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir.

Authors:  Shuanghui Luo; Zhiying Wang; Mitesh Patel; Varun Khurana; Xiaodong Zhu; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2011-05-07       Impact factor: 5.875

Review 7.  Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.

Authors:  Olivia L Lanier; Miranda G Manfre; Claire Bailey; Zhen Liu; Zachary Sparks; Sandesh Kulkarni; Anuj Chauhan
Journal:  AAPS PharmSciTech       Date:  2021-03-14       Impact factor: 3.246

8.  Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption.

Authors:  Chun-Li Wang; Yang-Bin Fan; Hsiao-Hwa Lu; Tung-Hu Tsai; Ming-Cheng Tsai; Hui-Po Wang
Journal:  J Biomed Sci       Date:  2010-09-06       Impact factor: 8.410

Review 9.  Advances in the use of prodrugs for drug delivery to the eye.

Authors:  Pranjal Taskar; Akshaya Tatke; Soumyajit Majumdar
Journal:  Expert Opin Drug Deliv       Date:  2016-07-21       Impact factor: 6.648

Review 10.  Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.